AN2 Therapeutics, Inc. (ANTX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AN2 Therapeutics, Inc. on June 20, 2025, covering events that occurred on June 17, 2025, and June 19, 2025. The Company is a Delaware corporation with its principal executive offices in Menlo Park, California, and its common stock trades on The Nasdaq Global Select Market under the symbol "ANTX".
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The report focuses exclusively on a specific securities transaction.
Material Changes and Transactions
Under Item 3.02, the Company reported unregistered sales of equity securities involving the issuance of pre-funded warrants in exchange for common stock held by Coastlands Capital Partners LP ("Coastlands Capital").
- June 17, 2025 Transaction: Coastlands Capital exchanged 2,500,000 shares of common stock for a pre-funded warrant to acquire 2,500,000 shares.
- June 19, 2025 Transaction: Coastlands Capital exchanged 300,000 shares of common stock for a pre-funded warrant to acquire 300,000 shares.
- Total Shares Exchanged: 2,800,000 shares of common stock were converted into pre-funded warrants.
- Warrant Terms: The warrants have an exercise price of $0.00001 per share, do not expire until fully exercised, and are subject to standard anti-dilution adjustments.
- Beneficial Ownership Blocker: The warrants include a provision preventing exercise if it would cause the holder's beneficial ownership to exceed 9.99% of outstanding shares. This limit can be adjusted to up to 19.99% with 61 days' notice.
- Regulatory Basis: The issuance was made without registration under Section 3(a)(9) of the Securities Act of 1933.
Guidance, Outlook, and Risks
The filing does not provide management commentary, financial guidance, or an outlook for future periods. No specific risks or contingencies were disclosed beyond the standard terms of the warrant agreement and the reliance on the Section 3(a)(9) exemption.
Key Facts for Investor Verification
- Verify the total number of shares outstanding to calculate the precise impact of the 9.99% beneficial ownership blocker on Coastlands Capital's ability to exercise the warrants.
- Confirm the current cash position of the Company, as the exchange of common stock for pre-funded warrants does not generate immediate cash proceeds.
- Review the full text of the Pre-Funded Warrant (Exhibit 4.1) for specific details on adjustment mechanisms and exercise procedures.
- Monitor future filings for any notice from Coastlands Capital to increase the beneficial ownership limit from 9.99% to 19.99%.